Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00046137 · ClinicalTrials.gov registry record · Phase 3

Combined Use of Teriparatide and Raloxifene in Postmenopausal Women With Osteoporosis

A Phase 3 study of Osteoporosis, Postmenopausal, sponsored by Eli Lilly and Company.

Completed
Registry status
Phase 3
Development phase
13
Study locations

NCT00046137 is a Phase 3 study of Osteoporosis, Postmenopausal that has completed, run by Eli Lilly and Company. The trial reports 13 study locations across 11 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00046137, a Phase 3 study of Osteoporosis, Postmenopausal, has completed, sponsored by Eli Lilly and Company.

COMPLETED
Registry status
Phase 3
Development phase
13
Study locations

Study Summary

The purpose of this study is to compare treatment with both teriparatide and raloxifene with teriparatide alone. The study will evaluate any side effects that may be associated with the two drugs and may help to determine whether teriparatide and raloxifene together can help patients with osteoporosis more than teriparatide alone.

Conditions Studied

Osteoporosis, Postmenopausal

Interventions

  • DRUG placebo
  • DRUG raloxifene
  • DRUG teriparatide

Study Locations (13)

California

  • "For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at 1-877-CTLILLY(1-877-285-4559) or speak with your personal physician". - Anaheim
  • "For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at 1-877-CTLILLY(1-877-285-4559) or speak with your personal physician". - Oakland

Maryland

  • "For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at 1-877-CTLILLY(1-877-285-4559) or speak with your personal physician". - Baltimore
  • "For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at 1-877-CTLILLY(1-877-285-4559) or speak with your personal physician". - Hagerstown

Florida

  • "For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at 1-877-CTLILLY(1-877-285-4559) or speak with your personal physician". - Altamonte Springs

Illinois

  • "For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at 1-877-CTLILLY(1-877-285-4559) or speak with your personal physician". - Chicago

Iowa

  • "For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at 1-877-CTLILLY(1-877-285-4559) or speak with your personal physician". - Cedar Rapids

New Jersey

  • "For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at 1-877-CTLILLY(1-877-285-4559) or speak with your personal physician". - Voorhees Township

Ohio

  • "For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at 1-877-CTLILLY(1-877-285-4559) or speak with your personal physician". - Cleveland

Oklahoma

  • "For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at 1-877-CTLILLY(1-877-285-4559) or speak with your personal physician". - Oklahoma City

Trial Details

FieldValue
Phase Phase 3

Sponsor

Eli Lilly and Company

1,341 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00046137

The ClinicalTrials.gov registry entry for NCT00046137 describes a study currently listed as completed, categorized as Phase 3. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Osteoporosis, Postmenopausal appearing as the primary indexed condition, and to 3 interventions - of which placebo is the first listed.

NCT00046137 reports 13 study locations spanning 11 distinct geographic areas - top geographies include California, Maryland, Florida.

Frequently Asked Questions

What is clinical trial NCT00046137 about?

NCT00046137 is a clinical study titled "Combined Use of Teriparatide and Raloxifene in Postmenopausal Women With Osteoporosis". The purpose of this study is to compare treatment with both teriparatide and raloxifene with teriparatide alone. The study will evaluate any side effects that may be associated with the two drugs and may help to determine whether teriparatide and raloxifene together can help patients with osteoporos...

What is the current status of trial NCT00046137?

This trial is currently completed. It is a Phase 3 study.

What conditions does trial NCT00046137 study?

This clinical trial studies the following conditions: Osteoporosis, Postmenopausal.

What interventions are being tested in trial NCT00046137?

The interventions under investigation include: placebo (DRUG), raloxifene (DRUG), teriparatide (DRUG).

Who is sponsoring clinical trial NCT00046137?

This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00046137 being conducted?

This trial has 13 study locations across California, Florida, Illinois, Iowa, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Osteoporosis, Postmenopausal

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Osteoporosis, Postmenopausal

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.